Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Medtronic plc buy marge

Medtronic plc
Start price
€69.98
29.07.15 / 50%
Target price
€73.96
18.07.16
Performance (%)
15.92%
End price
€79.70
18.07.16
Summary
This prediction ended on 18.07.16 with a price of €79.70. The BUY prediction by marge finished with a performance of 15.92%. marge has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Medtronic plc 1.480% 1.480% -6.454% -8.251%
iShares Core DAX® 2.992% 3.220% 4.271% 53.697%
iShares Nasdaq 100 -1.584% -3.172% 24.749% 76.697%
iShares Nikkei 225® -2.254% -9.924% 43.518% 60.793%
iShares S&P 500 -0.009% 1.641% 20.967% 62.807%

Comments by marge for this prediction

In the thread Medtronic plc diskutieren
Prediction Buy
Perf. (%) 15.92%
Target price 73.964
Change
Ends at 18.07.16

Marktführer in cardiac and vascular, minimally invasive therapies, diabetes, and restorative therapies

  • Medtronic offers investors exposure to best-in-class maker of medical devices.
  • The company has a long history of returning value to shareholders and is a dividend aristocrat.
  • The company can leverage its acquisition of Covidien to gain exposure to emerging markets.



  • Medtronic shows strong historical performance, and I believe the company is in a sweet spot going forward and will greatly benefit from the Covidien deal for a long time to come. With the deal completed, the company expects free cash flow to total $40 billion over the next 5 years, which is up from $29 billion in the previous 5 years. Free cash flow is the basis to a strong company, because it allows the company the flexibility to reinvest in itself, pay down debt and return value to shareholders, and Medtronic has a terrific history of doing all three.

    • marge 
    0
    Report Share
    29.07.15
    Prediction Buy
    Perf. (%) 15.92%
    Target price 73.964
    Change
    Ends at 18.07.16

    (Laufzeit überschritten)

    marge 
    0
    Report Share
    18.07.16